Schrödinger, Inc.

Issued on behalf of VentriPoint Diagnostics Ltd.

VANCOUVER, BC, Jan. 29, 2026 /CNW/ -- Equity-Insider.com News Commentary – The global AI medical imaging market exploded to a staggering $2.57 trillion in 2026 as the entire healthcare ecosystem ditched trial-and-error medicine for AI-native diagnostic precision and autonomous operations^[1]. This massive movement has pushed the AI drug discovery sector to $1.81 billion, powered by "federated learning" models that use high-frequency sensing to collapse development timelines from years into months^[2]. This new Diagnostic Data Core is creating massive tailwinds for VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Recursion Pharmaceuticals (NASDAQ: RXRX), Tempus AI (NASDAQ: TEM), Schrodinger (NASDAQ: SDGR) and Eli Lilly (NYSE: LLY) as they bridge the gap between old-school hardware and high-fidelity digital control.

Big data in healthcare has now reached a projected $132.32 billion in 2026, fueled by the urgent need for real-time, autonomous diagnostic resilience in every clinical workflow^[3]. Simultaneously, digital pathology platforms have surged to $2.01 billion as AI-powered biomarker prediction becomes the primary value driver for software-as-a-service architectures^[4]. We are witnessing a total "diagnostic-edge" convergence where MRI-grade software isn't just a tool--it's the primary engine for proactive life-extension and institutional ROI across the 2026 cycle.

Ventripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) is building a subscription business around technology that converts standard 2D ultrasound images into detailed 3D heart models with MRI-level accuracy. The system delivers precise cardiac assessments at a fraction of the cost and complexity of traditional MRI imaging.

Strong investor demand recently doubled the company's private placement from $500,000 to $1 million. The capital will fund commercialization activities, manufacturing scale-up, regulatory submissions across additional markets, and operational requirements as the company transitions from development to revenue generation.

The latest strategic move focuses on proving economic value rather than just clinical capability. Ventripoint engaged Summit Sciences, a specialized healthcare consulting firm, to develop ROI models that show hospitals exactly what they will save. These models integrate real-world data to demonstrate measurable returns through process improvements, enhanced diagnostic accuracy, and optimized resource allocation.

"We are excited to partner with Dana and Summit Sciences to elevate our financial modeling capabilities," said Hugh MacNaught, President and CEO of

Ventripoint Diagnostics. "Dana's extensive expertise in healthcare transformation, combined with Summit Sciences' proven track record in data-driven consulting, will enable us to deliver even more compelling value propositions to our customers. This initiative underscores our commitment to not only advancing cardiac care through technology but also ensuring that our solutions make strong economic sense for healthcare providers worldwide."

Dana Friesen leads Summit Sciences as CEO, bringing more than 15 years of experience in financial analysis and ROI optimization within the medical device sector. The firm has delivered billions in cumulative savings for clinical partners. Friesen's work with indigenous health networks aligns with Ventripoint's expansion into underserved markets.

The company announced a partnership with Nisga'a Valley Health Authority establishing a model for delivering advanced cardiac imaging to remote and Indigenous communities. The collaboration uses a hub-and-spoke design where local providers acquire ultrasound scans and transmit them digitally to specialists at a central hub for rapid interpretation.

Ventripoint appointed David Swetlow as Chief Financial Officer. Swetlow brings more than 15 years of senior management experience from high-growth medical technology companies including Sernova, Ondine, Protox, HealthPricer, and QLT. Management views the appointment as a key step in executing a commercial strategy designed to accelerate market adoption and drive revenue growth.

The company also issued a corporate update detailing its Device-as-a-Service subscription model. Management believes this approach shortens sales cycles and builds recurring revenue streams while making the technology accessible to more healthcare facilities without requiring large upfront capital investments.

CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://equity-insider.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint/

In other industry developments and happenings in the market include:

Recursion Pharmaceuticals (NASDAQ: RXRX) reported positive Phase 1b/2 results from its TUPELO trial showing REC-4881 achieved a 43% median reduction in polyp burden after 12 weeks of treatment in familial adenomatous polyposis patients. The investigational MEK1/2 inhibitor demonstrated durable efficacy with 82% of patients maintaining reductions at week 25, twelve weeks after stopping therapy, representing a 53% median decrease from baseline.

"These Phase 2 results mark a meaningful validation of the Recursion OS," said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion Pharmaceuticals. "An unbiased phenotypic insight from our platform and driven by AI--linking MEK1/2 inhibition to APC loss-of-function biology--has now translated into rapid, substantial, and durable reductions in polyp burden in patients."

The company's AI-driven platform identified REC-4881 as the first MEK1/2 inhibitor studied clinically for FAP, a disease affecting over 50,000 patients across the US and EU5 with no approved pharmacotherapy. Recursion Pharmaceuticals plans to engage the FDA in first half 2026 to define a potential registration pathway while expanding trial enrollment from patients aged 55 and older to those 18 and above.

Tempus AI (NASDAQ: TEM) has launched Paige Predict, a suite of AI-powered digital pathology applications that analyze hematoxylin and eosin whole slide images to predict clinically actionable biomarkers. Following the acquisition of Paige in 2025, the solution addresses tissue scarcity challenges by predicting the likely presence or absence of relevant biomarkers directly from a single H&E slide, offering physicians insights even when tissue samples are insufficient for full molecular profiling.

"Tissue can be scarce, but insights don't have to be," said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus. "Paige Predict overcomes one of the biggest barriers in NGS by delivering actionable information to inform critical testing decisions for patient care when sequencing isn't feasible."

Paige Predict analyzes H&E images to predict the likelihood of 123 biomarkers and oncogenic molecular pathways in 16 cancer types including NSCLC, prostate, breast, pancreatic, and colorectal. Built using a combined multimodal cohort containing de-identified data on over 200,000 patients, results are automatically delivered with clinical reports to ordering physicians.

Schrodinger (NASDAQ: SDGR) has announced a collaboration with Eli Lilly (NYSE: LLY) to make TuneLab, a platform designed to accelerate drug discovery through advanced artificial intelligence capabilities, available in LiveDesign. TuneLab will be made available in Schrodinger's widely used enterprise informatics platform as a priority interface for participating biotech companies to access TuneLab workflows.

"As a leader in computational drug discovery, Schrödinger is pleased to partner with Lilly TuneLab," said Pat Lorton, chief technology officer and chief operating officer, software at Schrodinger. "We are pleased that LiveDesign will be a priority platform partner for TuneLab workflows, reflecting the demand for a unified enterprise informatics solution that democratizes access to AI models, physics-based calculations, and experimental data across discovery teams."

Schrodinger has a long history of working with partners to accelerate drug discovery and is leveraging this collaboration to expand the use of digital drug design methods. TuneLab uses a privacy-first federated learning approach, allowing Lilly and partner companies to use the platform while keeping proprietary data separate and private.

Article Source: https://equity-insider.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint/ 

CONTACT:

Equity Insider: info@equity-insider.com

(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity-Insider.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. ("BAY") There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES:

1. https://www.globenewswire.com/news-release/2026/01/23/3224892/0/en/AI-in-Medical-Imaging-Market-Size-to-Hit-Nearly-USD-22-97-Trillion-by-2035-Driven-by-Rising-Demand-for-Early-Disease-Detection-and-Workflow-Automation.html
2. https://www.globenewswire.com/news-release/2026/01/19/3220751/0/en/AI-in-Drug-Discovery-Market-Research-Report-2026-2040-NVIDIA-Insilico-Medicine-Google-DeepMind-Pfizer-and-Roche-Leveraging-AI-Platforms-to-Accelerate-Development-Timelines-and-Redu.html
3. https://www.towardshealthcare.com/insights/big-data-in-healthcare-market-sizing
4. https://www.prnewswire.com/news-releases/digital-pathology-market-growing-at-9-9-cagr-to-2031-as-ai-adoption-accelerates-says-a-2026-mordor-intelligence-report-302663208.html

Logo - https://mma.prnewswire.com/media/2840019/Equity_Insider_Logo.jpg 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-native-data-core-triggers-multi-trillion-dollar-healthcare-structural-shift-302671551.html

Issued on behalf of Avant Technologies Inc.

VANCOUVER, BC, Dec. 9, 2025 /PRNewswire/ -- Equity Insider News Commentary – Traditional pharmaceutical strategies are giving ground as breakthrough approvals for gene therapies and mRNA platforms target previously untreatable rare diseases with precision interventions^[1]. Healthcare systems integrating AI diagnostic tools now match therapies to individual genetic profiles rather than treating broad populations with reactive symptom management^[2]. Five companies positioned at this convergence include Avant Technologies, Inc. (OTCQB: AVAI), Beam Therapeutics Inc. (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP), Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), and Schrödinger, Inc. (NASDAQ: SDGR).

Market analysts tracking precision medicine expansion project the sector will grow from $119 billion in 2025 to $471 billion by 2034 as genomics-driven therapeutics capture share from conventional small molecules^[3]. Institutional momentum including longevity research initiatives and accelerated regulatory pathways for companion diagnostics create favorable conditions for developers addressing genetic disorders and metabolic dysfunction^[4].

Avant Technologies, Inc. (OTCQB: AVAI) has significantly strengthened the clinical validation for its lead development program, announcing that a newly published study from the Mayo Clinic reinforces the critical role of the "longevity protein" $\alpha$-Klotho in vascular health. The research, appearing in the Journal of the American Heart Association, demonstrates a strong association between declining $\alpha$-Klotho levels and arterial stiffness, endothelial dysfunction, and vascular calcification. This clinical data provides urgent scientific backing for Klothonova, the company's 50/50 joint venture with Singapore-based cell therapy pioneer Austrianova, which is developing a cell-based therapy designed to sustainably restore circulating $\alpha$-Klotho levels using genetically modified human cells.

"An ever-growing body of scientific literature, including this new Mayo Clinic study, confirms $\alpha$-Klotho as a master regulator of aging and longevity," said Chris Winter, CEO of Avant Technologies. "The age-related decline in $\alpha$-Klotho is implicated in a wide range of chronic diseases that appear reversible when Klotho levels are restored. Our encapsulated cell therapy approach has the potential to be a true game-changer—not only for cardiovascular health but for healthy longevity in general."

This scientific validation accelerates the momentum behind the transformative exclusive worldwide license Klothonova recently secured with Klothea Bio, Inc. The agreement grants the joint venture global rights to develop, manufacture, and commercialize Klothea Bio's proprietary Klotho-producing cells. These cells will be encapsulated using Austrianova's clinically validated Cell-in-a-Box® technology to create implantable therapies capable of sustained, localized delivery. Since its October 2025 launch, Klothonova has initiated preparatory work for GMP-manufacturing of the encapsulated Klotho-overexpressing cell line, with plans to advance into IND-enabling studies in the coming year.

Avant's strategic transformation extends beyond anti-aging through Insulinova, Inc., a joint venture with SGAustria Pte. Ltd. aimed at revolutionizing a diabetes treatment. This partnership will advance a proprietary differentiation process achieving high-efficiency conversion of stem cells into insulin-producing and regulating cells, targeting type 1 and insulin-dependent type 2 diabetes patients globally. Avant will provide initial funding over the next eight months to hit established criteria relevant for an efficient, sustainable, and reproducible diabetes treatment.

Both SGAustria and Austrianova utilize cell-encapsulation platforms backed by over 50 peer-reviewed publications representing decades of development. The potential market opportunity spans multiple therapeutic areas: the global Alzheimer's market is projected to reach $32.8 billion by 2033, cardiovascular disease remains the world's leading cause of death, and kidney disease affects 850 million people worldwide. The broader cell-based therapy market could reach $44 billion globally, representing urgent health crises requiring the innovative therapeutic solutions Avant is developing.

CONTINUED... Read this and more news for Avant Technologies at:

https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 

Beam Therapeutics Inc. (NASDAQ: BEAM) will present updated data from its BEACON Phase 1/2 clinical trial at the American Society of Hematology (ASH) Annual Meeting in December, advancing its base editing platform for sickle cell disease with severe vaso-occlusive crises. BEAM-101 represents a one-time, potentially disease-modifying therapy targeting the approximately 8 million people worldwide living with this devastating condition that severely affects multiple organs, diminishes quality of life, and shortens lifespan. The presentations will showcase both clinical outcomes and manufacturing advances, including enhanced mobilization techniques for the autologous CD34+ hematopoietic stem cells that are base-edited to increase fetal hemoglobin production.

"Approximately eight million people worldwide live with sickle cell disease, a condition that can severely affect the function of multiple organs, diminish quality of life, and result in a shortened life span. These patients have a significant unmet need for additional safe and effective treatment options," said Amy Simon, M.D., Chief Medical Officer of Beam Therapeutics. "BEAM-101, designed to be a one-time, disease-modifying therapy, has the potential to meaningfully improve outcomes for people with severe SCD."

The therapy mimics naturally occurring protective variants through precise base editing of hematopoietic stem cells, representing Beam's integrated platform approach that combines gene editing, delivery, and internal manufacturing capabilities to advance precision genetic medicines for serious diseases.

CRISPR Therapeutics (NASDAQ: CRSP) delivered strong third-quarter execution with positive Phase 1 data for CTX310 presented at the American Heart Association Scientific Sessions and published simultaneously in The New England Journal of Medicine, while CASGEVY momentum accelerated globally with nearly 300 patients referred to Authorized Treatment Centers. The company's first approved CRISPR therapy completed cell collection for approximately 165 patients and delivered infusions to 39 across all regions through September 30th, with Vertex projecting clear line of sight to over $100 million in total CASGEVY revenue this year. Beyond the commercial launch, CRISPR unveiled its novel SyNTase editing platform with CTX460 for alpha-1 antitrypsin deficiency, demonstrating greater than 90% mRNA correction and a potential best-in-class profile that expands the platform's therapeutic reach.

"This has been another strong quarter of execution and progress across our portfolio. CASGEVY momentum continues to build globally, reflecting growing patient engagement and clinical advancement," said Samarth Kulkarni, Ph.D., Chairman and CEO of CRISPR Therapeutics. "Additionally, positive Phase 1 data for CTX310 presented in a late-breaking presentation at the American Heart Association Scientific Sessions and published in The New England Journal of Medicine, highlight the breadth and potential of our platform to address serious cardiovascular disease."

CRISPR Therapeutics maintains a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities as of September 30, 2025, supporting ongoing clinical trials for CTX112 across multiple autoimmune and oncology indications with broad updates expected by year-end.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) secured FDA alignment to resume its pivotal Phase 2 trial of RP-A501 for Danon disease in the first half of 2026, resolving the clinical hold in under three months and positioning its AAV cardiovascular gene therapy portfolio for advancement. The company received a March 28, 2026 PDUFA date for KRESLADI for severe leukocyte adhesion deficiency-I, making it eligible for a Rare Pediatric Disease Priority Review Voucher upon approval, while strengthening commercial readiness through key leadership appointments including Dr. Syed Rizvi as Chief Medical Officer, Christopher Stevens as Chief Operating Officer, and Sarbani Chaudhuri as Chief Commercial & Medical Affairs Officer.

"During the third quarter, we maintained disciplined execution and sharpened our strategic focus on Rocket's AAV cardiovascular gene therapy portfolio," said Gaurav Shah, M.D., CEO of Rocket Pharmaceuticals. "In under three months, we aligned with the FDA to resume the Phase 2 pivotal study of RP-A501 for Danon disease, an important milestone that underscores the FDA's collaborative approach and recognition of the urgent need for innovative therapies in rare cardiovascular disorders."

With cash, cash equivalents and investments totaling approximately $222.8 million and expected operational runway into the second quarter of 2027, Rocket is advancing RP-A601 toward a pivotal Phase 2 study in PKP2-ACM and preparing RP-A701 for first-in-human evaluation in BAG3-DCM, demonstrating the platform's potential across multiple rare cardiovascular genetic diseases.

Schrödinger, Inc. (NASDAQ: SDGR) delivered third-quarter total revenue of $54.3 million, up 54% year-over-year, driven by 28% software revenue growth to $40.9 million reflecting increasing industry demand for its computational platform. Drug discovery revenue reached $13.5 million as the company advances multiple programs including SGR-3515, its Wee1/Myt1 co-inhibitor progressing through Phase 1 dose escalation with initial data expected in the first half of 2026, while the FDA granted Orphan Drug Designation to SGR-1505 for Waldenström macroglobulinemia. SGR-6016 became the company's fifth development candidate as a brain-penetrant NLRP3 inhibitor with a planned mid-2026 clinical trial initiation, demonstrating the platform's ability to generate novel therapeutic candidates.

"Schrödinger delivered a solid third quarter with software revenue growth of 28%, reflecting the industry's increasing demand for our leading computational platform," said Ramy Farid, Ph.D., CEO of Schrödinger. "In our therapeutics portfolio, we are continuing to make strong progress advancing our collaborations and have increased our expectations for drug discovery revenue this year. Beyond our planned clinical investments to complete the Phase 1 dose-escalation studies for SGR-1505 and SGR-3515, we do not intend to advance discovery programs into the clinic independently. This shift toward a discovery-focused therapeutics R&D model has the potential to deliver significant long-term value through licensing, new ventures, and discovery collaborations."

With cash, cash equivalents and investments of approximately $401 million and expected savings of approximately $70 million from strategic realignment toward a platform-focused model, Schrödinger projects operational runway into the second quarter of 2027 while positioning its physics-based computational platform to enable therapeutic discoveries across multiple disease areas.

Source: https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors- need-to-know/ 

CONTACT:

Equity Insider

info@equity-insider.com

(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES CITED:

1.   https://www.hcplive.com/view/q2-2025-recap-7-top-fda-approvals

2.   https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/

3.   https://www.precedenceresearch.com/precision-medicine-market

4.   https://finance.yahoo.com/news/a4m-unveils-next-frontier-longevity-141500076.html 

Logo - https://mma.prnewswire.com/media/2840019/5663020/Equity_Insider_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/beyond-traditional-drugs-novel-platforms-targeting-hard-to-treat-conditions-302636904.html